Clinical and Economic Outcomes in Patients With Metastatic Urothelial Carcinoma Receiving First-Line Systemic Treatment (the IMPACT UC I Study)

BACKGROUND: The IMPACT UC I study assessed real-world treatment patterns, outcomes, healthcare resource utilization (HCRU), and costs in patients with metastatic urothelial carcinoma (mUC) receiving first-line (1L) systemic treatment after the FDA approval of 1L immune checkpoint inhibitor (ICI) mon...

Descripción completa

Detalles Bibliográficos
Autores principales: Bilen, Mehmet A, Robinson, Scott B, Schroeder, Amy, Peng, Jing, Kim, Ruth, Liu, Frank X, Bhanegaonkar, Abhijeet
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Genitourinary Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10485286/
https://www.ncbi.nlm.nih.gov/pubmed/37432283
http://dx.doi.org/10.1093/oncolo/oyad174

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10485286/
https://www.ncbi.nlm.nih.gov/pubmed/37432283
http://dx.doi.org/10.1093/oncolo/oyad174

Ejemplares similares